Regeneron And TriNetX Collaborate To Support Regeneron's Capabilities In Drug Discovery And Development, As Well As New Initiatives To Deliver Digital Health Solutions

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data

Collaboration will expand Regeneron's world-leading genomic and proteomic EHR-linked database

Growing database will continue to drive drug discovery and development and empower AI training algorithms to deliver digital health solutions of the future for consumers, patients and providers

TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and TriNetX® today announced a strategic collaboration to support Regeneron's capabilities in drug discovery and development, as well as new initiatives to deliver digital health solutions of the future for consumers, patients and providers. Regeneron gains the exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading phenotypic data network of approximately 300 million de-identified and anonymized patients. This collaboration will enable expansion of Regeneron's world-leading genomic and proteomic Electronic Health Record (EHR)-linked database, a key driver of the company's industry-leading therapeutics pipeline.

Under the collaboration, TriNetX will provide Regeneron with secure, licensed access to TriNetX's current and future de-identified health data from approximately 300 million individuals (170 million of whom are in the United States), sourced directly from its global network of health system partners. With privacy-preserving methods, Regeneron will have the capability to match a portion of TriNetX's de-identified/anonymized data to genomic and proteomic data generated by the Regeneron Genetics Center® (RGC®). Such matching will be conducted in accordance with all applicable data privacy laws, including HIPAA and GDPR.

The RGC has developed high-throughput and cost-efficient DNA sequencing and proteomics approaches to build the world's largest database of EHR-linked sequencing and proteomics data, in collaboration with over 150 life sciences and healthcare collaborators around the world. The collaboration with TriNetX will help Regeneron dramatically expand this already world-leading dataset to continue to drive drug discovery and development, while also empowering artificial intelligence (AI) training algorithms to deliver digital health solutions of the future.